|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The results of this pilot study indicate a possible involvement of miR-155 in surgery-induced angiogenesis and potential prognostic significance of high postoperative levels of circulating miR-195 in patients with breast cancer.
|
25503185 |
2014 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this review, we discuss the role of miR-155 in the acquisition of breast cancer drug resistance.
|
25744731 |
2015 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Urinary miR-155 levels were significantly higher in BC patients compared to healthy controls (1.49vs.0.25; p < 0.001).
|
25886191 |
2015 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Apart from that, miR-155 in breast cancer achieved the highest accuracy compared with miR-155 in other types of cancer.Results from meta-analysis suggested that miR-155 had great potential as a novel noninvasive biomarker for human cancer detection, particularly when breast cancer or Caucasian is involved.
|
26765436 |
2016 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The effect of genistein was determined on breast cancer cell viability, apoptosis, and expression of miR-155 and its targets.
|
26771440 |
2016 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results suggest that miR-155 might be involved in breast cancer pathogenesis and in tumor spreading to the lymph nodes, and that it might be used as biomarker for additional stratification of patients with invasive breast carcinomas with non-invasive component.
|
26889816 |
2016 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this work we show that MGP is significantly repressed by miR-155 in breast cancer MCF-7 cells, and concomitantly there is a stimulation of cell proliferation and cell invasiveness.
|
27009385 |
2016 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We further determined that miR-155 potently suppresses ErbB2 in breast cancer cells.
|
27065318 |
2016 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, through the anti-glycolytic effect and breakage of the JAK/STAT3/SOCS1 feedback loop via miR-155-5p, 3B may potentially serve as a potential therapeutic agent against breast cancer.
|
27470349 |
2016 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As a result, the relatively larger (<100 nm) particles precipitated by PEG5k clearly exhibited the greatest amount of epithelial cell adhesion molecule (EpCAM), from both breast cancer (MCF-7) and colon cancer (HCT116) cells, and a larger quantity of microRNA (miRNA) specific to breast cancer cells (miRNA155 for MCF-7) seemed to be contained in the PEG-precipitated particles.
|
27917441 |
2017 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Serum levels of miR-21 and miR-155 was significantly higher, while miR-365 was significantly lower in breast cancer as compared with healthy controls.
|
28203552 |
2017 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We observed that the oncogenic miR-155 level was down-regulated in the antitumor CTL against breast cancer, and it may be used as the effective treatment to eliminate the malignant cells in the breast cancer patients.
|
28338193 |
2017 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
There was a positive correlation between expression of FOXP3 and miR-155 in breast cancer cell lines and primary breast cancers.
|
28562349 |
2017 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Wound fluids affect miR-21, miR-155 and miR-221 expression in breast cancer cell lines, and this effect is partially abrogated by intraoperative radiation therapy treatment.
|
28943910 |
2017 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prediction Potential of Serum miR-155 and miR-24 for Relapsing Early Breast Cancer.
|
28994735 |
2017 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results suggested that MIAT acted as a competing endogenous RNA (ceRNA) to regulate the expression of dual specificity phosphatase 7 (DUSP7) by taking up miR-155-5p in breast cancer.
|
29100300 |
2017 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Soft agar colony formation assay and tumor xenografts showed inhibition of miR-155 could significantly reduce proliferation of cancer cells in vivo and vitro, which confirmed that miR-155 is an effective therapeutic target of breast cancer.
|
29103027 |
2018 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The developed biosensor not only was capable to identification of fully matched versus one-base mismatch miRNA-155 sequence, but also it could detect target miRNA-155 in spiked real human serum and extracts from human breast cancer cell-line samples.
|
29331901 |
2018 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
An ultrasensitive optical biosensor for microRNA-155 (miR-155) was developed to diagnose breast cancer at early stages.
|
29440644 |
2018 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, these data demonstrate the miR-155 is a key regulator of glucose metabolism in breast cancer.
|
29527004 |
2018 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results of luciferase reporter assays verified that miR-155 was a direct target of XIST in breast cancer.
|
29550489 |
2018 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Simultaneous downregulation of miR-21 and miR-155 through oleuropein for breast cancer prevention and therapy.
|
29905007 |
2018 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, detection of the miRNA-17-5p, miR-155 and miRNA-222 expression levels in serum samples is significant promising molecular markers for early breast cancer diagnosis.
|
29925280 |
2019 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
By virtue of these advantages, the PA nanoprobes may provide a powerful platform for in situ detection of miR-155 and thus real-time monitoring of tumorigenesis and drug response in breast cancer.
|
29961324 |
2018 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, the role of miR‑155 in breast cancer cell invasion and metastasis remains to be elucidated.
|
30015868 |
2018 |